{"id":2190,"date":"2023-10-25T14:21:55","date_gmt":"2023-10-25T08:51:55","guid":{"rendered":"https:\/\/alpexpharma.in\/?p=2190"},"modified":"2023-10-25T14:23:33","modified_gmt":"2023-10-25T08:53:33","slug":"imatinib-mesylate-tablets-contract-manufacturing","status":"publish","type":"post","link":"https:\/\/alpexpharma.in\/imatinib-mesylate-tablets-contract-manufacturing\/","title":{"rendered":"Unveiling the World of Imatinib Mesylate Tablets: A Dive into Third-Party Manufacturing"},"content":{"rendered":"
Imatinib Mesylate, a revolutionary drug, has transformed the landscape of cancer treatment. Marketed under various trade names, such as Gleevec and Glivec, it is a tyrosine kinase inhibitor used primarily in the management of chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GISTs), and certain other cancers.<\/p>\n
In the dynamic pharmaceutical industry, third-party manufacturing has emerged as a strategic avenue for producing a diverse range of pharmaceutical products. Imatinib Mesylate tablets are no exception. Let’s unravel the layers of third-party manufacturing and its implications in the production of this groundbreaking medication.<\/p>\n